Ocera Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ocera Therapeutics Inc.
Since going public, the company’s share price has flopped, its board has seen a flurry of appointments and resignations over the past year, and now the company is facing investor lawsuits.
SVB health care advisor Jonathan Norris anticipates more consolidation in devices ahead with many mid-cap public companies looking to acquire innovative technologies to grow, and pushing the “big guys to have to figure out how to move faster.”
In an interview with Medtech Insight, Another newcomer to the handheld ultrasound market weighed in on the competitive environment.
The new version of Philips' Lumify gives clinicians access to pulse wave Doppler ultrasound technology, providing real-time blood flow information.
- Other Names / Subsidiaries
- Tranzyme Pharma